Organic compounds
    1.
    发明授权
    Organic compounds 有权
    有机化合物

    公开(公告)号:US08530522B2

    公开(公告)日:2013-09-10

    申请号:US13128825

    申请日:2009-11-10

    摘要: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

    摘要翻译: 本发明涉及2-氨基-2- [2-(4-(C 2 -C 20 - 烷基 - 苯基)乙基]丙烷-1,3-二醇的结晶形式和水合物,特别是在 治疗或预防各种自身免疫病症。

    Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester
    2.
    发明授权
    Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester 失效
    已知噻吩羧酸十二氢环戊二烯(a)菲基酯的多晶型物

    公开(公告)号:US07683048B2

    公开(公告)日:2010-03-23

    申请号:US10522358

    申请日:2003-07-28

    IPC分类号: A61K31/58 C07D215/04

    CPC分类号: C07J33/00 C07J33/002

    摘要: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R, 17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10, 11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described.

    摘要翻译: 3-甲基噻吩-2-羧酸(6S,9R,10S,11S,13S,16R,17R)-9-氯-6-氟-11-羟基-17-甲氧基羰基-10,13,16- 三甲基-3-氧代-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊二烯并[a]菲-17-基酯。 结晶形式具有抗炎活性,稳定性好。 还描述了制备晶体形式的方法。

    Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester
    3.
    发明申请
    Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester 失效
    已知噻吩羧酸十二氢环戊二烯(a)菲基酯的多晶型物

    公开(公告)号:US20060166954A1

    公开(公告)日:2006-07-27

    申请号:US10522358

    申请日:2003-07-28

    IPC分类号: C07D215/04 A61K31/58

    CPC分类号: C07J33/00 C07J33/002

    摘要: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described.

    摘要翻译: 3-甲基噻吩-2-羧酸(6S,9R,10S,11S,13S,16R,17R)-9-氯-6-氟-11-羟基-17-甲氧基羰基-10,13,16- 三甲基-3-氧代-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊二烯并[a]菲-17-基酯。 结晶形式具有抗炎活性,稳定性好。 还描述了制备晶体形式的方法。

    ORGANIC COMPOUNDS
    4.
    发明申请
    ORGANIC COMPOUNDS 有权
    有机化合物

    公开(公告)号:US20110229501A1

    公开(公告)日:2011-09-22

    申请号:US13128825

    申请日:2009-11-10

    摘要: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

    摘要翻译: 本发明涉及2-氨基-2- [2-(4-(C 2 -C 20 - 烷基 - 苯基)乙基]丙烷-1,3-二醇的结晶形式和水合物,特别是在 治疗或预防各种自身免疫病症。

    Organic Compounds
    8.
    发明申请
    Organic Compounds 审中-公开
    有机化合物

    公开(公告)号:US20140051766A1

    公开(公告)日:2014-02-20

    申请号:US13964817

    申请日:2013-08-12

    IPC分类号: C07C215/28

    摘要: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

    摘要翻译: 本发明涉及2-氨基-2- [2-(4-(C 2 -C 20 - 烷基 - 苯基)乙基]丙烷-1,3-二醇的结晶形式和水合物,特别是在 治疗或预防各种自身免疫病症。

    Crystalline form G of imatinib mesylate
    10.
    发明授权
    Crystalline form G of imatinib mesylate 失效
    甲磺酸伊马替尼的结晶形式G.

    公开(公告)号:US08507515B2

    公开(公告)日:2013-08-13

    申请号:US13183557

    申请日:2011-07-15

    申请人: Michael Mutz

    发明人: Michael Mutz

    IPC分类号: A61K31/505

    CPC分类号: C07D401/04 C07D401/14

    摘要: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.

    摘要翻译: 公开了甲磺酸伊马替尼(F,G,H,I和K)的结晶形式及其各自的表征。